Sana Kliniken Duisburg GmbH

The medical center is at the forefront of research in thrombosis and hemostasis, focusing on conditions such as congenital antithrombin deficiency. This rare genetic disorder affects the body's ability to regulate blood clotting, leading to an increased risk of thrombotic events.

• Congenital Antithrombin Deficiency
• Thrombotic Events Management
• Thromboembolic Event Prevention

Through innovative therapies like Atenativ, the center is pioneering new approaches to manage and prevent complications during surgical procedures or childbirth in affected patients.

Specializing in neuro-oncology, the center conducts cutting-edge research on high-risk medulloblastoma, a challenging pediatric brain tumor. The focus is on improving outcomes through advanced radiotherapy techniques and novel chemotherapy regimens.

• High-Risk Medulloblastoma
• Hyperfractionated-Accelerated Radiotherapy
• High-Dose Chemotherapy

By exploring different therapeutic strategies, the center aims to enhance survival rates and quality of life for young patients diagnosed with this aggressive cancer.

The center is a leader in the field of immunotherapy for glioblastoma, focusing on the use of personalized vaccines derived from the patient's own immune cells. This approach aims to boost the body's natural defenses against this aggressive brain tumor.

• Dendritic Cell Vaccines
• Glioblastoma Treatment
• Survival Improvement Strategies

By integrating these vaccines with standard treatments, the center is working to significantly improve overall survival rates for newly diagnosed glioblastoma patients.